Synektik (SNTP) Q3 2026 earnings summary

Executive summary

• Revenue for the nine months ended 30 June 2026 rose 52% year-over-year to PLN 733.4 million, driven by strong growth in medical equipment and IT solutions sales, as well as maintenance and measurement services.

• Net profit from continuing operations increased 61% year-over-year to PLN 138.0 million, with total comprehensive income reaching PLN 386.4 million, including a non-cash gain from the demerger of PLN 261.3 million.

• The Group completed a significant demerger, transferring the cardiotracer project and Center for Research on New Compounds to Syn2bio SA, resulting in a one-time gain and a reduction in equity.

Financial highlights

• Operating profit (EBIT) for the nine months was PLN 173.8 million, up from PLN 107.5 million year-over-year.

• EBITDA from continuing operations rose 55% to PLN 189.6 million, with an EBITDA margin of 25.8%.

• Net cash flows from operating activities increased to PLN 141.4 million, while net cash flows from financing activities were negative at PLN -125.7 million, mainly due to dividend payments.

• Book value per share as of 30 June 2026 was PLN 25.11.

Outlook and guidance

• Management anticipates continued growth in sales of medical equipment, IT, and maintenance services, supported by higher public healthcare investment and an expanding product portfolio.

• Expansion in surgical robotics, especially in Poland and new markets such as Ukraine, is expected to drive future results.

• Recurring revenue from services and consumables is projected to increase due to a growing installed base and higher device utilization.